Who is sponsoring NCT02592174?

NCT02592174 is sponsored by ANRS, Emerging Infectious Diseases.

What condition does NCT02592174 study?

NCT02592174 studies HIV-1 Infection.

Is NCT02592174 still recruiting?

NCT02592174 is currently completed. Last updated 8 January 2018.

Last reviewed 2018-01-08 · How we verify

NCT02592174: HAND55-70

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevalence, Characteristics and Risk Factors of HIV-Associated Neurocognitive Disorders in Subjects Between the Ages of 55 and 70 Years: An Exposed/Unexposed Cross Sectional Study

Completed NA Last updated 8 January 2018

What this trial tests

NA trial testing Health related quality of life and social and demographic informations in HIV-1 Infection in 220 participants. Completed in 27 October 2017.

Timeline

26 January 2016

Primary endpoint
27 October 2017

27 October 2017

Quick facts

Lead sponsor	ANRS, Emerging Infectious Diseases
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	220
Start date	26 January 2016
Primary completion	27 October 2017
Estimated completion	27 October 2017
Sites	6 locations across France

Drugs / interventions tested

Health related quality of life and social and demographic informations
Neurocognitive assessment
cerebral images sub-study

Conditions studied

HIV-1 Infection — all drugs for HIV-1 Infection →

Sponsor

ANRS, Emerging Infectious Diseases — full company profile →

Who can join

Adults 55 to 70, any sex, with HIV-1 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective is to measure the prevalence of according to the Frascati classification in a HIV-infected population aged between 55 and 70 years (exposed group) and to compare it with the prevalence of HIV-Associated Neurocognitive Disorders (HAND) in unexposed subjects from the general population-based cohort CONSTANCES, matching subjects on age, gender, geographical origin and socioprofessional category.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Increased Prevalence of Neurocognitive Impairment in Aging People Living With Human Immunodeficiency Virus: The ANRS EP58 HAND 55-70 Study.
Makinson A, Dubois J, Eymard-Duvernay S, Leclercq P, et al · · 2020 · cited 25× · PMID 31755936 · DOI 10.1093/cid/ciz670
NK Cells Acquire CCR5 and CXCR4 by Trogocytosis in People Living with HIV-1.
Vo DN, Leventoux N, Campos-Mora M, Gimenez S, et al · · 2022 · cited 10× · PMID 35632444 · DOI 10.3390/vaccines10050688
Abstract Supplement Abstracts from AIDS 2022, the 24th International AIDS Conference, 29 July - 2 August 2022, Montreal, Canada & Virtual.
· 2022 · cited 8× · PMID 35916394 · DOI 10.1002/jia2.25935

Verify or expand the search:

Other recruiting trials for HIV-1 Infection

Currently open trials in the same condition.

NCT06660498 — Pomalidomide as an Immune-enhancing Agent for the Control of HIV · Phase 1, PHASE2 · recruiting
NCT06602622 — Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI · Phase 4 · recruiting
NCT05705349 — DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053) · Phase 3 · active not recruiting
NCT05631093 — A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Vir · Phase 3 · active not recruiting
NCT05630755 — A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Vir · Phase 3 · active not recruiting

Other ANRS, Emerging Infectious Diseases trials

Trials by the same sponsor.

NCT07098481 — Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy · Phase 4 · not yet recruiting
NCT06913959 — HIV-1 Non-group M in Cameroon : Study of Genotypic and Phylogenetic Diversity (OBSOCAM) · not yet recruiting
NCT07113106 — Dose Escalation Trial of CD40.Pan.CoV Vaccine, Adjuvanted or Not, as a Booster in Adult Healthy Volunteers · Phase 1, PHASE2 · recruiting
NCT05222945 — A Study to Determine the Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Pa · NA · not yet recruiting
NCT06522256 — Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of H · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02592174 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ANRS, Emerging Infectious Diseases
Last refreshed: 8 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02592174.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing